


## A2A receptor antagonist 1

<b>Cat. No.:</b>	HY-102024		
<b>CAS No.:</b>	443103-97-7		
<b>Molecular Formula:</b>	C <sub>16</sub> H <sub>12</sub> FN <sub>5</sub> O		
<b>Molecular Weight:</b>	309.3		
<b>Target:</b>	Adenosine Receptor		
<b>Pathway:</b>	GPCR/G Protein		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 25 mg/mL (80.83 mM; Need ultrasonic)					
		Solvent Concentration	Mass	1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM		3.2331 mL	16.1655 mL	32.3311 mL
		5 mM		0.6466 mL	3.2331 mL	6.4662 mL
10 mM			0.3233 mL	1.6166 mL	3.2331 mL	
Please refer to the solubility information to select the appropriate solvent.						
<b>In Vivo</b>	<ol style="list-style-type: none"> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 40% PEG300 &gt;&gt; 5% Tween-80 &gt;&gt; 45% saline Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution</li> <li>Add each solvent one by one: 10% DMSO &gt;&gt; 90% corn oil Solubility: ≥ 2.5 mg/mL (8.08 mM); Clear solution</li> </ol>					

### BIOLOGICAL ACTIVITY

<b>Description</b>	A2A receptor antagonist 1 (CPI-444 analog) is an antagonist of both adenosine A <sub>2A</sub> receptor and A <sub>1</sub> receptor with K <sub>i</sub> values of 4 and 264 nM, respectively <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Ki: 4 nM (adenosine A <sub>2A</sub> receptor), 264 nM (A <sub>1</sub> receptor) <sup>[1]</sup>
<b>In Vitro</b>	A2A receptor antagonist 1 (CPI-444 analog) is a potent adenosine A <sub>2A</sub> receptor antagonist, selective over the A <sub>1</sub> receptor and demonstrates its binding activity with K <sub>i</sub> values of 4 and 264 nM, respectively <sup>[1]</sup> .

---

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Gillespie RJ, et al. Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-aryl purines. *Bioorg Med Chem Lett*. 2008 May 1;18(9):2924-9.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA